Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Biotechnology

Healthcare
$3.53 -3.40%

-$0.24 today

Market cap
$103.02M
Beta
1.73
P/E (TTM)
-40.8
EPS (TTM)
-$0.17
52W Low $3.71High $8.74

Volume 0.86M

Average 0.65M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$29.52M

FY 2025 · Annual

Net Income

-$26.55M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0951K675K00
Cost of Revenue0000572K
Gross Profit0951K675K0(572K)
Gross Margin—100.0%100.0%——
Research & Development6.08M12.44M12.9M20.01M9.12M
Selling, General & Admin2.9M6.57M8.55M12.1M20.4M
Operating Expenses8.98M19M21.45M32.12M28.95M
Depreciation & Amortization13K161K284K428K572K
EBITDA(9.38M)(17.89M)(30.18M)(36.23M)(25.91M)
EBITDA Margin—-1881.3%-4470.8%——
Operating Income(8.98M)(18.05M)(20.77M)(32.12M)(29.52M)
Operating Margin—-1898.2%-3077.6%——
Interest Income00615K1.26M1.01M
Interest Expense628K6K82K71K71K
Other Income / Expenses(1.04M)(6K)(9.77M)(4.61M)2.96M
Income Before Tax(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Pre-Tax Margin—-1898.8%-4525.0%——
Income Tax Expense00000
Net Income(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Net Margin—-1898.8%-4525.0%——
EPS (Basic)(8.60)(1.20)(1.28)(5.60)(1.67)
EPS (Diluted)(8.60)(1.20)(1.28)(5.60)(1.67)
Weighted Avg Shares1.17M1.51M2.45M6.7M158.87M
Weighted Avg Shares (Diluted)1.17M1.51M2.45M6.7M158.87M

UNCY Earnings Waterfall · TTM

NASDAQ:UNCY · Revenue to Net Income

Key Ratios

EPS$-1.71
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-13.0
P/S Ratio0.0

Analysis

$0 of revenue converted into -$39.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.71, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipOct 29, 2026
3Initial statement of beneficial ownershipOct 1, 2026
8-KCurrent reportSep 29, 2026
8-KCurrent reportSep 28, 2026
SC 13G/ASC 13G/A filingAug 14, 2026

How much revenue does UNCY generate?

Unicycive Therapeutics, Inc. (UNCY) reported $0.00 of revenue in fiscal 2025.

Is UNCY profitable?

Unicycive Therapeutics, Inc. (UNCY) reported -$26.55M of net income.